Lung cancer organoids in translational research: Bridging basic science, drug development, and clinical therapeutics

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2025-07-07 DOI:10.1016/j.critrevonc.2025.104840

Jiequn Ma , Suoni Li , Xi Zhang , Peixi Zhao , Bin Zhao , Jianren Yue , Le Han , Jie Bai , Zheng Zhao , Yili Zhang

{"title":"Lung cancer organoids in translational research: Bridging basic science, drug development, and clinical therapeutics","authors":"Jiequn Ma , Suoni Li , Xi Zhang , Peixi Zhao , Bin Zhao , Jianren Yue , Le Han , Jie Bai , Zheng Zhao , Yili Zhang","doi":"10.1016/j.critrevonc.2025.104840","DOIUrl":null,"url":null,"abstract":"<div><div>Lung cancer remains a leading cause of cancer-related deaths globally, presenting significant clinical challenges despite advancements in therapeutic strategies. Recent developments have highlighted the potential of lung cancer organoids as a promising tool to bridge basic science, drug development, and clinical therapeutics. This review focuses on the innovative role of lung cancer organoids in translational research, particularly their ability to integrate and accelerate the development of personalized treatment strategies. By mimicking patient-specific tumor microenvironments, lung cancer organoids provide an unparalleled platform for drug screening, evaluation of immune therapies, and assessment of anti-angiogenesis treatments. We posit that lung cancer organoids represent a cutting-edge, multidisciplinary tool with the potential to revolutionize cancer treatment and improve patient outcomes through enhanced translational research.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104840"},"PeriodicalIF":5.5000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842825002288","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer remains a leading cause of cancer-related deaths globally, presenting significant clinical challenges despite advancements in therapeutic strategies. Recent developments have highlighted the potential of lung cancer organoids as a promising tool to bridge basic science, drug development, and clinical therapeutics. This review focuses on the innovative role of lung cancer organoids in translational research, particularly their ability to integrate and accelerate the development of personalized treatment strategies. By mimicking patient-specific tumor microenvironments, lung cancer organoids provide an unparalleled platform for drug screening, evaluation of immune therapies, and assessment of anti-angiogenesis treatments. We posit that lung cancer organoids represent a cutting-edge, multidisciplinary tool with the potential to revolutionize cancer treatment and improve patient outcomes through enhanced translational research.

查看原文本刊更多论文

转化研究中的肺癌类器官：连接基础科学、药物开发和临床治疗

肺癌仍然是全球癌症相关死亡的主要原因，尽管治疗策略取得了进展，但仍提出了重大的临床挑战。最近的发展突出了肺癌类器官作为基础科学、药物开发和临床治疗的桥梁工具的潜力。本文综述了肺癌类器官在转化研究中的创新作用，特别是它们整合和加速个性化治疗策略发展的能力。通过模拟患者特异性肿瘤微环境，肺癌类器官为药物筛选、免疫疗法评估和抗血管生成治疗评估提供了无与伦比的平台。我们认为，肺癌类器官代表了一种前沿的多学科工具，有可能通过加强转化研究彻底改变癌症治疗和改善患者预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.